Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
关于我们
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Suzhou
- 类型
- 私人持股
地点
-
主要
获取路线
BioBAY
CN，Suzhou
Eluminex Biosciences Limited员工
-
Charles Semba (仙波), MD
Chief Medical Officer and Board Member. Developing global innovative therapeutics for dermal aesthetics and vision-threatening diseases. Look better.…
-
Jinzhong Zhang (JZ)
Founder, Chairman & CEO at Eluminex Biosciences
-
Youqin Tian, MD, PhD
Senior Vice President, Product Development/Head of Regulatory Affairs, at Eluminex Biosciences
-
Chen Jessie
HR Director at Eluminex Biosciences